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Polycystic liver disease (PCLD) is characterized by the growth of fluid-filled cysts of biliary epithelial origin in the
liver. Although the disease is often asymptomatic, it can, when severe, lead to complications requiring surgical
therapy. PCLD is most often associated with autosomal dominant polycystic kidney disease (ADPKD); however,
families with an isolated polycystic liver phenotype without kidney involvement have been described. The clinical
presentation and histological features of polycystic liver disease in the presence or absence of ADPKD are indis-
tinguishable, raising the possibility that the pathogenetic mechanisms in the diseases are interrelated. We ascertained
two large families with polycystic liver disease without kidney cysts and performed a genomewide scan for genetic
linkage. A causative gene, PCLD, was mapped to chromosome 19p13.2-13.1, with a maximum LOD score of 10.3.
Haplotype analysis refined the PCLD interval to 12.5 cM flanked by D19S586/D19S583 and D19S593/D19S579.
The discovery of genetic linkage will facilitate diagnosis and study of this underdiagnosed disease entity. Identification
of PCLD will be instrumental to an understanding of the pathogenesis of cyst formation in the liver in isolated
PCLD and in ADPKD.
Polycystic liver disease (PCLD [MIM 174050]) is one of
the hepatobiliary fibropolycystic diseases characterized
by an overgrowth of biliary epithelium and supportive
connective tissue (Torres 1996). The clinical entity of
PCLD in autosomal dominant polycystic kidney disease
(ADPKD [MIM 173900 and MIM 173910]) has been
well studied. There is an age-dependent increase of he-
patic cyst prevalence, from 20% of patients in the 3d
decade of life to 75% by the 7th decade of life (Milu-
tinovic et al. 1980; Grunfeld et al. 1985; Gabow et al.
1990). At any stage, women are more likely than men
to have more and larger cysts (Grunfeld et al. 1985;
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Gabow et al. 1990), and nulliparous women who have
never used estrogens are less likely to have cysts than
are those who have been pregnant and/or used hormones
(Gabow et al. 1990).
Autosomal dominant PCLD also occurs indepen-
dently of ADPKD. Although likely an overestimate of
the prevalence of isolated PCLD, the frequency of poly-
cystic kidneys in old autopsy or surgical series of PCLD
has been reported to be on the order of 50%–60%
(Comfort et al. 1952; Melnick 1955). Nevertheless, fam-
ilies with PCLD either without renal cysts or with only
a few renal cysts have been described (Sotaniemi et al.
1979), and a large retrospective study of medicolegal
autopsies in Finland also has suggested that PCLD exists
as an entity separate from ADPKD (Karhunen and
Tenhu 1986). Most recently, several reports have dem-
onstrated that PCLD is a unique entity, genetically dis-
tinct from PKD1 and PKD2, the genes responsible for
ADPKD (Pirson et al. 1996; Iglesias et al. 1999). In the
present study, we examined two large kindreds segre-
gating PCLD as a dominant trait (fig. 1). Ascertainment
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Figure 1 Pedigrees of families 1 and 2, which have isolated PCLD, and associated chromosome 19p haplotypes. The black bars denote
the haplotypes at informative markers segregating with the disease phenotype. Black symbols denote affected individuals; white symbols
containing an “N” denote unaffected individuals; white symbols containing cross hairs denote individual whose affection status is unknown;
white symbols not containing any of the aforementioned items denote individuals not at risk. The numbers to the upper right of the symbols
are the ages (in years) at ultrasound examination. The marker order is given to the left of each generation in the pedigrees; intermarker genetic
distances are shown in figure 3. Question marks denote unknown alleles. Individuals II:5, III:16, III:17, and III:18 in family 1 and individuals
II:6, II:13, III:4, and III:14 in family 2 define the centromeric boundary of the disease interval at D19S593/579. Individuals II:1 and III:19 in
family 1 define the telomeric boundary at D19S406; III:3 also shows recombination between PCLD and D19S586.
required that at least one member of each family have
both symptomatic PCLD treated by surgery and neither
kidney involvement nor a family history of ADPKD. We
used these families in a genomewide scan for linkage
and established the existence of a locus for PCLD, on
chromosome 19p13.2-13.1.
The participants were studied at theMayo Clinic Gen-
eral Clinical Research Center. Informed consent was ob-
tained. All subjects underwent a medical history inter-
view, physical examination, serum biochemical deter-
minations and complete cell count, standard magnetic-
resonance head imaging, magnetic-resonance angiog-
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Figure 2 Computerized tomograms of the abdomen, illustrating extensive PCLD in the absence of renal cysts in (A panels) individual
III:7 in family 1 and (B panels) individual III:11 in family 2.
raphy of the circle of Willis (Huston et al. 1996), ultra-
sonography of liver and kidneys, and echocardiography,
including 2D and 2D-guidedM-mode echocardiography
and Doppler ultrasound with color-flow imaging (Nish-
imura et al. 1985; Marks et al. 1989). In some patients,
computed tomographies of the abdomen, previously ob-
tained for clinical indications, also were available for
review. All clinical evaluations were done without
knowledge of linkage status. There is no known rela-
tionship between the two kindreds.
The clinical criteria used to diagnose PCLD were a
history consistent with autosomal dominant inheritance
and the presence of either any hepatic cysts, in subjects
!40 years old, or at least four hepatic cysts, in individ-
uals 140 years old (fig. 2). No members of either kindred
fulfilled criteria for the diagnosis of autosomal dominant
polycystic kidney disease (Bear et al. 1992; Ravine et al.
1994). Individuals 140 years old who had no liver cysts
were considered as unaffected. Individuals 140 years old
who had one to three hepatic cysts were designated as
having an “indeterminate” phenotype, since there is an
age-dependent occurrence of simple liver cysts in the
general population (Gaines and Sampson 1989; Care-
mani et al. 1993). Individuals !40 years old who had
no cysts also were considered as having an indeterminate
phenotype—an extrapolation from ADPKD, in which
the liver-cystic disease generally lags behind the kidney
cysts and where, in the absence of kidney cysts, the age
of 30 years is used as the cutoff for exclusion of disease
(Bear et al. 1992; Ravine et al. 1994). Student’s t-test
and Fischer’s exact test were used to compare the clinical
parameters of the affected and unaffected individuals.
The P values reported are two-tailed, and .05 was used
as the criterion of statistical significance.
Genomic DNA from individual family members was
prepared from whole blood, by use of the PureGene kit
(Gentra Systems). One DNA sample from family 1 (from
individual II:1) was extracted from paraffin-embedded
tissue (Ex-Wax; Oncor). The genome scan utilized the
Marshfield (version 8a) human genome–scanning set of
polymorphic markers (Center for Medical Genetics,
Marshfield Medical Research Foundation). Fluorescent
marker analysis was performed by an ABI 377 Prism
sequencer at the Human Genome Program core at the
Albert Einstein College ofMedicine. The allele data were
analyzed sequentially by the GENESCAN and GENO-
TYPER programs (ABI). Allele calls by GENOTYPER
were checked manually for accuracy. The marker data
were then checked for Mendelian inheritance within a
pedigree, by GENEBASE (ABI), as well as by inspection
after they were entered into CYRILLIC (Cherwell Sci-
entific). Two-point linkage analysis used MLINK, and
multilocus analysis used the LINKMAP program of
LINKAGE (version 5.1) (Lathrop et al. 1985), both in
the FASTLINK implementation (version 4.1p) (Cot-
tingham et al. 1993; Scha¨ffer et al. 1994). The disease-
allele frequency in the population was set at .0002, the
phenocopy rate was set at the same frequency, and the
heterozygous disease penetrance was assumed to be .95.
Marker-allele frequencies were set at 1/n, where n is the
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Figure 3 Genetic map of markers used in this study. Distances
(in cM) were obtained from the Marshfield sex-averaged map.
D19S394 is not genetically mapped but, rather, on the basis of the
Chromosome 19–p Arm Metric Physical Map (Lawrence Livermore
Laboratory) maps 1 Mb centromeric to D19S586p. Markers defining
the PCLD genetic interval are in boldface.
Table 1
Two-Point LOD Scores, between PCLD and Chromosome 19
Markers
MARKER
LOD SCORE AT v p
.00 .01 .05 .10 .20 .30 .40
D19S565 4.33 4.28 4.08 3.78 2.99 1.97 .80
D19S591 .35 2.75 3.88 3.98 3.33 2.19 .83
D19S424 5.63 5.58 5.27 4.76 3.55 2.21 .86
D19S406 1.37 1.37 1.35 1.28 1.00 .60 .20
D19S586 2.89 4.30 4.56 4.31 3.40 2.22 .88
D19S558 9.68 9.58 9.06 8.28 6.44 4.28 1.83
D19S221 7.05 6.99 6.63 6.05 4.62 2.93 1.12
D19S593 .97 .77 .62 1.25 1.4 .99 .37
D19S579 9.18 2.75 .15 1.06 1.67 1.35 .58
D19S561 13.62 6.31 2.11 .29 .95 .96 .45
number of alleles observed. After linkage was estab-
lished, further genetic analysis to confirm and refine the
interval used backbone markers and genetic distances
from the Marshfield sex-averaged linkage map, accessed
through The Genome Database. Haplotypes were as-
signed on the basis of the principle of minimization of
intermarker recombination.
We confirmed that neither kindred segregated a gene
for ADPKD, by excluding genetic linkage to both
16p13.3 (PKD1) and 4q21-23 (PKD2) (data not
shown). Power analysis demonstrated that, in each fam-
ily, linkage could be independently established, with a
LOD score 13.0 (data not shown). On the basis of the
expectation that the rate of false-positive diagnosis (i.e.,
at least four liver cysts in unaffected individuals) is less
than the rate of false-negative diagnosis, we chose to use
family 2 in the initial genome scan. Genetic linkage to
chromosome 19 was suggested when D19S591 gave a
LOD score 13.0 at recombination fraction (v) 0. To fur-
ther evaluate this finding, both kindreds were analyzed
with markers throughout 19p (figs. 1 and 3). Families
1 and 2 independently support linkage to 19p13.2-13.1,
with peak two-point LOD scores of 4.54 and 5.14, re-
spectively, at D19S558 ( ). The combined two-vp 0
point data are given in table 1. Multipoint analysis sug-
gests that the most likely location for the disease locus
is centered around D19S558 and D19S221 (maximum
LOD score 10.3; see fig. 4). The 3-LOD-support con-
fidence interval spans a region of ∼20 cM within the
interval bounded by D19S406 and D19S593/D19S579.
Inspection of the predicted haplotypes (fig. 1) reveals
that there are no obligate recombinants between the dis-
ease and either D19S558 or D19S221. Obligate recom-
binants are observed with all other makers in the anal-
ysis. Individual II:4 in family 1 has the entire affected
haplotype yet is clinically unaffected at age 75 years,
suggesting that PCLD is not completely penetrant.
The centromeric boundary for the PCLD interval oc-
curs at D19S593/D19S579. This is supported by the
multipoint analysis and the apparent recombinant hap-
lotypes in individuals II:5, III:16, III:17, and III:18 in
family 1 and individuals II:6, II:13, III:4, and III:14 in
family 2 (fig. 1). There are three apparent recombination
events, all occurring in family 1, between the disease
locus and telomeric markers. Results of study of indi-
viduals II:1, III:3, and III:19 define the telomeric recom-
binatorial boundary as being at D19S406, and the 3-
LOD-support interval is consistent with this boundary.
Also, individual III:3, who is affected with six liver cysts
at age 50 years, further shows apparent recombination
between D19S586 and PCLD. D19S586 was not infor-
mative in II:1 and III:19.
We examined family 1, using additional markers—
D19S413, D19S583, and D19S394 (fig. 3). D19S413 is
not recombined with the disease haplotype in the af-
fected individual, II:1, whereas unaffected individual III:
19 has the normal D19S413 allele (data not shown). In
both individuals, the recombination defining the telo-
meric boundary of the PCLD genetic interval occurs in
the region between D19S406 and D19S413. However,
in individual III:3, D19S586 and D19S583 are infor-
mative and recombine with the disease locus whereas
D19S394 does not, placing the recombination in the
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Figure 4 Multipoint analysis with 10 chromosome 19 markers.
The maximum LOD score is obtained with D19S221/D19S558, and
the 3-LOD support interval is between D19S406 and D19S593/
D19S579.
interval between these loci. This analysis suggests that
the telomeric recombinatorial boundary for PCLD is
defined at D19S586/D19S583, refining the location of
the PCLD gene to a 12.5-cM interval betweenD19S586/
D19S583 and D19S593/D19S573 (fig. 3).
A total of 49 at-risk individuals underwent clinical
evaluations for this study; 47 had a complete evaluation,
and 2 underwent only ultrasonography of the liver and
kidneys. In addition, DNA was available from two clin-
ically affected individuals who were deceased at the time
of the study. Of the 49 participants, 22 were affected by
PCLD, 17 were not affected, and 10 had indeterminate
clinical diagnoses. All individuals with at least four liver
cysts at any age carried the disease haplotype, suggesting
that this criterion is adequate for differentiation between
most of the individuals in the population who are af-
fected and those who have a few isolated liver cysts. Of
the 10 at-risk individuals with indeterminate clinical di-
agnoses, 3 (III:2, III:4, and IV:1, all from family 1) carry
the affected disease haplotype (fig. 1). III:2, a woman,
and III:4, a man, have one to three liver cysts at an
advanced age, whereas IV:1, another woman, has no
cysts at age 33 years. Individual II:15 in family 1 and
individual II:8 in family 2 are classified as unknown,
with one to three liver cysts at an advanced age. They
both carry a portion of the disease haplotype but have
a recombination within in the PCLD critical interval,
which, at the time of the study, obviated genetic diag-
nosis. Of the remaining five individuals with an “un-
known” clinical diagnosis, all are predicted to be un-
affected, on the basis of genetic analysis; three of these
individuals (individual IV:2 in family 1 and individuals
III:2 and IV:1 in family 2) are classified as unknown
solely on the basis of an age of !40 years and the absence
of cysts, and the two others (individuals II:1 and III:5
in family 2) have one to three cysts at an advanced age.
Finally, as discussed above, the disease is not penetrant
in individual II:4 in family 1, at age 75 years.
The group of 46 patients who underwent evaluations
at theMayo Clinic General Clinical Research Center and
for whom a genetic diagnosis could be established com-
prised 26 genetically affected individuals and 20 genet-
ically unaffected individuals. Abnormal mitral valve leaf-
lets were observed more frequently in the group with
PCLD (35% vs. 5%; ). The prevalence of in-Pp .028
tracranial aneurysms (one in each group) was low and
not different between affected and unaffected individ-
uals. No difference in the prevalence of either renal
cysts or hypertension was detected. The severity of
PCLDwas graded from 0 to 6, depending on the number
of cysts detected by ultrasound (0 p 0 cysts, 1p 1–3
cysts, 2p 4–6 cysts, 3p 7–10 cysts, 4p 11–15 cysts,
5 p 16–20 cysts, and 6 p 120 cysts). PCLD was more
severe in affected women than in affected men (4.4
vs. ; ). The more severe liver cys-2.3 1.8 1.2 Pp .009
tic disease in women and the higher prevalence of mitral
valve leaflet abnormalities in affected individuals rein-
force the similarities between the phenotypes of isolated
PCLD and ADPKD and raise the possibility that PCLD,
like ADPKD, is a systemic disorder.
The 12.5-cM PCLD interval is too large to be prac-
tical for positional cloning even as the genomic se-
quencing for the region is being completed. Further
refinement of the recombinatorial boundaries will be
necessary before saturation mutation detection of ex-
pressed sequences becomes feasible. However, a posi-
tional candidate approach based on the current un-
derstanding of the disease pathogenesis could identify
PCLD. In this regard, no putative proteins with se-
quence similarity to PKD1 or PKD2 were identified in
the interval by BLAST searches of the available ge-
nomic sequence dynamically translated in six reading
frames. PKD1 is thought to function as a cell-surface
receptor active in cell-cell or cell-matrix contact, and
PKD2 is a putative calcium-channel protein whose ac-
tivity may be interdependent with that of PKD1 (Em-
mons and Somlo 1999). Genes expressed in the liver
that have potential functions related to the function of
PKD1 and PKD2 may serve as candidates.
The most recent Chromosome 19–p ArmMetric Phys-
ical Map (Lawrence Livermore Laboratory) lists 28
genes in the interval between D19S586 and D19S593/
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D19S579. Mutations in the voltage-dependent calcium
channel gene, CACNA1A, which maps to the interval,
already have been associated with spinocerebellar atax-
ias (Jodice et al. 1997), and mutations in NOTCH3
cause cerebral autosomal dominant arteriopathy with
subcotical infarcts and leukoencephalopathy (Joutel et
al. 1996). Since PKD2 may function as an intracellular
calcium channel (Cai et al. 1999), calreticulin (gene
CALR), which codes for a calcium-binding luminal en-
doplasmic-reticulum chaperone involved in intracellular
calcium homeostasis and cell adhesion (Michalak et al.
1998), is considered a candidate. The receptor-associ-
ated Janus kinase (gene TYK2) has been implicated in
growth hormone–receptor signaling and acute-phase re-
sponse in the liver (Kim and Baumann 1997; Hellgren
et al. 1999) and may also be a candidate if it is active
in biliary epithelial cells. The transcription factor coded
by NFI-X is expressed in liver (Chaudhry et al. 1997),
and its pleiotropic functions may include hormone-re-
sponsive gene expression (reviewed in Gronostajski
2000). ICAM-1 and ICAM-3, the genes for intercellular
adhesion molecules that are members of the immuno-
globulin superfamily, map to this region, but no clear
function in biliary epithelia has been attributed to these
adhesion molecules. The remainder of the known genes
in this region either have reported tissue distributions or
putative functions (if known) that do not suggest them
as strong positional candidates. At present, the most
prudent course toward identification of PCLD remains
a combination of refinement of the genetic interval and
continued gene identification based on the genomic se-
quence of the region. The identification of PCLD will
have an impact on the understanding of liver-cyst path-
ogenesis and may point the way toward nonsurgical
therapy for patients affected with symptomatic liver
disease.
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